Four Chemotherapy Drugs Remain in Shortage Until October
Cisplatin, carboplatin, oxaliplatin, and ifosfamide remain in active shortage, with full resupply of some formulations not expected until October 2026, according to the American Society of Health-System Pharmacists. These chemotherapy drugs are essential for treating breast, lung, ovarian, testicular, bladder, and head and neck cancers. Manufacturers have provided updated timelines for when supply will normalize. The shortages affect hospitals and health systems managing cancer treatment protocols.
Medicaid managed care organizations covering oncology services must work with network providers to manage formulary alternatives, prior authorization protocols, and care coordination for members requiring these chemotherapy agents during the shortage period.
Managed Care · Pharmacy
You might also like